NCT04572542

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer： a Single-arm, Multicenter， Prospective Phase II Study

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: The First Affiliated Hospital of Xiamen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .

Conditions

• Locally Advanced or Metastatic Gastric Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg
DRUG	Apatinib Mesylate	Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday
DRUG	nab-paclitaxel	nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2

Timeline

• Start date: 2020-01-01
• Primary completion: 2021-06-01
• Completion: 2022-06-01
• First posted: 2020-10-01
• Last updated: 2020-10-01

Locations

1 site across 1 country: China